Supermax Corporation Berhad

Supermax Corporation Berhad, an investment holding company, manufactures, distributes, and markets medical gloves and contact lenses in Malaysia. The company offers various types of natural rubber and nitrile latex gloves, as well as personal protective equipment. It is also involved in the trading, importing, and distribution of latex gloves; generation of biomass energy; marketing and distribution of healthcare products and medical devices; and property holding activities. The company sells its products to laboratories, pharmacists, hospitals, doctors, and surgeons under the Supermax, Aurelia, and Maxter brands. It also exports its products to approximately 165 countries, including the United States, the European Union, the Middle East, Asia, and the South Pacific countries. The company was founded in 1987 and is headquartered in Sungai Buloh, Malaysia.

Supermax Corporation Berhad trades as SPMXF on OTC. The company is classified in Healthcare / Medical - Instruments & Supplies and reports in USD.

The current profile places the business in Medical - Instruments & Supplies. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows $781.85M of revenue and -$160.40M of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Supermax Corporation Berhad can be compared against peers such as Columbia Care Inc., Opthea Limited, Claritas Pharmaceuticals, Inc., Dong Fang Hui Le Inc., Guerbet S.A., Opsens Inc..

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $458.59M, beta of 0.16, and return on equity of N/A.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

SPMXF currently shows total debt of N/A and beta of 0.16. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.supermax.com.my

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.